Sie sind hier: Startseite Termine Market Access of Biosimilars in the EU - Value Assessment/HTA?
x
Um unsere Webseite für Sie optimal zu gestalten und fortlaufend verbessern zu können, verwenden wir Cookies. Durch die weitere Nutzung der Webseite stimmen Sie der Verwendung von Cookies zu. Weitere Informationen zu Cookies erhalten Sie in unserer Datenschutzerklärung.

Market Access of Biosimilars in the EU - Value Assessment/HTA?

With experts from HAS, NICE, RADS Denmark, G-BA, CatSalut Value assessment for biosimilars and the regulation of the substitution - these hot topics will be discussed at the meeting.
  • With experts from HAS, NICE, RADS Denmark, G-BA, CatSalut Value assessment for biosimilars and the regulation of the substitution - these hot topics will be discussed at the meeting.

    Aims and objectives:
    Biosimilars are playing an increasingly important role in the national healthcare systems of the EU. But market access and reimbursement are facing challenges:

    - Is there a consensus regarding whether or not HTA assessment is necessary for biosimilars?
    - How can a substitution be regulated and potentially also be enforced?

    These and further topics will be addressed in an intensive discussion among experts from five national HTA bodies.

    Topics:
    - Market access for biosimilars in Germany - the current challenges and regulatory trends at a glance
    - Market access for biosimilars in the UK, France, Germany, Spain/Catalonia and Denmark
    - Current discussion: Value assessment for biosimilars foreseen? Substitution regulated?

    52.5063153 13.3443265
    • MAHP Newsletter
Was
  • MAHP Newsletter
Wann 14.12.2015
von 18:00 bis 20:30
Veranstaltungsort Pullman Berlin Schweizerhof
Stadt Berlin
Kontaktname
Kontakttelefon +49 6221 500-680
Zielgruppe This meeting addresses the needs of managing directors and co-workers in the pharmaceutical industry who are involved in market access and healthcare management of biosimilars.
Especially those who are responsible for the international business will benefit from this meeting.
Termin übernehmen vCal
iCal

Aims and objectives:
Biosimilars are playing an increasingly important role in the national healthcare systems of the EU. But market access and reimbursement are facing challenges:

- Is there a consensus regarding whether or not HTA assessment is necessary for biosimilars?
- How can a substitution be regulated and potentially also be enforced?

These and further topics will be addressed in an intensive discussion among experts from five national HTA bodies.

Topics:
- Market access for biosimilars in Germany - the current challenges and regulatory trends at a glance
- Market access for biosimilars in the UK, France, Germany, Spain/Catalonia and Denmark
- Current discussion: Value assessment for biosimilars foreseen? Substitution regulated?

Direktbuchung

Weitere Informationen über diesen Termin…

FORUM Institut für Management GmbH

Programm

1512238_Klappkarte.pdf — PDF document, 223 kB (229,075 bytes)
Artikelaktionen
abgelegt unter: